Analyst Price Targets — BBOT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 9:15 am | John Newman | Canaccord Genuity | $23.00 | $7.66 | TheFly | BridgeBio Oncology initiated with a Buy at Canaccord |
| February 10, 2026 9:13 pm | Laura Prendergast | Stifel Nicolaus | $23.00 | $10.84 | TheFly | BridgeBio Oncology initiated with a Buy at Stifel |
| January 9, 2026 11:29 am | — | Raymond James | $24.00 | $13.30 | TheFly | BridgeBio Oncology initiated with an Outperform at Raymond James |
| January 8, 2026 12:46 pm | — | Morgan Stanley | $18.00 | $12.92 | TheFly | BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley |
| December 5, 2025 12:36 pm | — | Morgan Stanley | $20.00 | $11.54 | TheFly | BridgeBio Oncology initiated with an Overweight at Morgan Stanley |
| September 17, 2025 10:59 am | — | Leerink Partners | $25.00 | $10.79 | TheFly | BridgeBio Oncology initiated with an Outperform at Leerink |
| September 15, 2025 10:15 am | Robert Burns | H.C. Wainwright | $27.00 | $9.73 | TheFly | BridgeBio Oncology initiated with a Buy at H.C. Wainwright |
| September 4, 2025 10:10 am | — | Oppenheimer | $23.00 | $10.08 | TheFly | BridgeBio Oncology initiated with an Outperform at Oppenheimer |
| August 15, 2025 11:03 am | Biren Amin | Piper Sandler | $21.00 | $9.70 | TheFly | BridgeBio Oncology initiated with an Overweight at Piper Sandler |
Latest News for BBOT
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026.
Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203 Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and…
Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average
BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65% objective response rate and 100% disease control in KRAS G12C NSCLC, exceeding results from approved competitors. Further mature data readouts for BBOT's pipeline are expected in 2H26, representing key catalysts for share…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BBOT.
U.S. House Trading
No House trades found for BBOT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.